Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
Winston A, Stöhr W, Antinori A, Amieva H, Perré P, De Wit S, Reynes J, Gompels M, dʼArminio Monforte A, Gatell JM, Grarup J, Pozniak A, Babiker A, Raffi F, Richert L; NEAT 001ANRS 143 Study Group. Winston A, et al. Among authors: richert l. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):185-192. doi: 10.1097/QAI.0000000000001189. J Acquir Immune Defic Syndr. 2017. PMID: 27749603 Clinical Trial.
Cognitive disorders in HIV-infected patients: are they HIV-related?
Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, Mercié P, Greib C, Richert L, Neau D, Catheline G, Dehail P, Dabis F, Morlat P, Dartigues JF, Chêne G; S CO3 Aquitaine Cohort. Bonnet F, et al. Among authors: richert l. AIDS. 2013 Jan 28;27(3):391-400. doi: 10.1097/QAD.0b013e32835b1019. AIDS. 2013. PMID: 23079813
Handgrip strength is only weakly correlated with physical function in well-controlled HIV infection: ANRS CO3 Aquitaine Cohort.
Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P; Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Richert L, et al. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e25-7. doi: 10.1097/QAI.0b013e3182a03db8. J Acquir Immune Defic Syndr. 2014. PMID: 24419068 No abstract available.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Among authors: richert l. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Diabetes and cognitive decline in a French cohort of patients infected with HIV-1.
Dufouil C, Richert L, Thiébaut R, Bruyand M, Amieva H, Dauchy FA, Dartigues JF, Neau D, Morlat P, Dehail P, Dabis F, Bonnet F, Chêne G; ANRS CO3 Aquitaine Study Group. Dufouil C, et al. Among authors: richert l. Neurology. 2015 Sep 22;85(12):1065-73. doi: 10.1212/WNL.0000000000001815. Epub 2015 Jul 8. Neurology. 2015. PMID: 26156515 Free PMC article.
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group. Bernardino JI, et al. Among authors: richert l. Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30. Lancet HIV. 2015. PMID: 26520926 Clinical Trial.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.
George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, Spire B, Volny-Anne A, West B, Molina JM, Horban A, Fox J, Pozniak A, Vella S, Termote M, Raffi F; NEAT 001/ANRS 143 Study Group. George EC, et al. Among authors: richert l. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):519-526. doi: 10.1097/QAI.0000000000001844. J Acquir Immune Defic Syndr. 2018. PMID: 30234665 Free PMC article. Clinical Trial.
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.
Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; NEAT001/ANRS143 Trial Study Group. Ammassari A, et al. Among authors: richert l. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):481-490. doi: 10.1097/QAI.0000000000001834. J Acquir Immune Defic Syndr. 2018. PMID: 30365452 Free PMC article. Clinical Trial.
308 results